Literature DB >> 26384449

An economic analysis of adult hepatitis B vaccination in China.

Hui Zheng1, Fu-zhen Wang2, Guo-min Zhang2, Fu-qiang Cui2, Zhen-hua Wu2, Ning Miao2, Xiao-jin Sun2, Xiao-feng Liang2, Li Li3.   

Abstract

BACKGROUND AND
OBJECTIVE: With the universal infant hepatitis B vaccination (HepB) program, China has made remarkable achievements to prevent and control hepatitis B. In order to further reduce hepatitis B virus (HBV) infection, the Chinese government is considering implementing a widespread adult HBV vaccination campaign. We performed an economic analysis of two different adult HepB vaccination strategies for 21-59-years-olds: vaccination without screening and screening-based vaccination.
METHODS: Cost-benefit analyses were conducted. All 21-59-year-olds were divided into two groups: young adults (ages 21-39) and middle-aged adults (ages 40-59). Costs and benefits were estimated using the direct cost and societal (direct and indirect costs) perspectives. All costs and benefits were adjusted to 2014 US dollars, where future values were discounted at a 3% annual rate. We calculated benefit-cost ratios (BCRs) of the two vaccination strategies for the two different age groups. Sensitivity analyses varied key parameters within plausible ranges.
RESULTS: Among young adults, the direct and societal BCRs for a vaccination campaign with no screening would be 1.06 and 1.42; with a screening-based vaccination campaign, the model estimated the direct and societal BCRs would be 1.19 and 1.73. Among middle-aged adults, the direct and societal BCRs for a vaccination campaign without screening would be 0.59 and 0.59; with a screening-based vaccination campaign, the model estimated the direct and societal BCRs would be 0.68 and 0.73.
CONCLUSION: The results of our study support a HepB vaccination campaign for young adults. Additionally, a vaccination campaign with screening appeared to provide greater value than a vaccination without screening.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adult; Hepatitis B; Vaccination

Mesh:

Substances:

Year:  2015        PMID: 26384449     DOI: 10.1016/j.vaccine.2015.09.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013.

Authors:  Yuan-Sheng Chen; Hui Zheng; Yan-Min Liu; Fu-Zhen Wang; Zhen-Hua Wu; Ning Miao; Xiao-Jin Sun; Guo-Min Zhang; Fu-Qiang Cui; Xiao-Feng Liang
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

2.  Building the evidence for hepatitis B vaccination programs for students and researchers working with biological samples in Indian Institutes of Higher Education.

Authors:  Simran Malik; Ranjan Saurav Das; Tila Khan; Ausath G Anto; Lokesh Rajagopal; Sangeeta Das Bhattacharya
Journal:  Hum Vaccin Immunother       Date:  2021-12-17       Impact factor: 3.452

3.  Factors associated with adults' perceived need to vaccinate against hepatitis B in rural China.

Authors:  Lijie Yu; Jian Wang; Knut R Wangen; Ruohan Chen; Elizabeth Maitland; Stephen Nicholas
Journal:  Hum Vaccin Immunother       Date:  2016-04-04       Impact factor: 3.452

4.  Hepatitis B immunization for indigenous adults, Australia.

Authors:  Andre Louis Wattiaux; J Kevin Yin; Frank Beard; Steve Wesselingh; Benjamin Cowie; James Ward; Kristine Macartney
Journal:  Bull World Health Organ       Date:  2016-09-16       Impact factor: 9.408

5.  Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China.

Authors:  Fuqiang Cui; Lipin Shen; Li Li; Huaqing Wang; Fuzhen Wang; Shengli Bi; Jianhua Liu; Guomin Zhang; Feng Wang; Hui Zheng; Xiaojin Sun; Ning Miao; Zundong Yin; Zijian Feng; Xiaofeng Liang; Yu Wang
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

6.  Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses.

Authors:  Liv Solvår Nymark; Alex Miller; Anna Vassall
Journal:  Pharmacoecon Open       Date:  2021-05-04

Review 7.  A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.

Authors:  Cameron M Wright; Lydia Boudarène; Ninh Thi Ha; Olivia Wu; Neil Hawkins
Journal:  BMC Public Health       Date:  2018-03-20       Impact factor: 3.295

8.  Effect of a Community-Based Hepatitis B Virus Infection Detection Combined with Vaccination Program in China.

Authors:  Xinyao Liu; Wuqi Qiu; Yan Liang; Wei Zhang; Qian Qiu; Xinxin Bai; Guolin Dai; Hao Ma; Hongpu Hu; Wei Zhao; Guangyu Hu
Journal:  Vaccines (Basel)       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.